Results and Impact of LIFT-TB Operational Research

Through LIFT-TB, TB Alliance worked across seven high-burden countries—Indonesia, Kyrgyzstan, Myanmar, the Philippines, Ukraine, Uzbekistan, and Vietnam—to accelerate the adoption and scale-up of shorter, more effective treatments for drug-resistant tuberculosis (DR-TB). By combining operational research, technical assistance, and health system strengthening, LIFT-TB helped reduce the time from treatment approval to widespread access from the typical 7–9 years to approximately three.

Across participating countries, real-world evidence demonstrated treatment success rates of approximately 91%, while reducing treatment duration from up to 18–24 months to just six months. All seven countries incorporated these regimens into national guidelines—many ahead of schedule—supported by locally generated evidence on safety, feasibility, and effectiveness.

Beyond direct implementation, LIFT-TB strengthened national health systems by training more than 12,000 clinical and laboratory personnel and enhancing key infrastructure for sustainable rollout. Participating countries also emerged as global leaders, using their experience to inform and accelerate adoption in additional countries. Through initiatives like PeerLINC, these learnings continue to be shared globally, extending LIFT-TB’s impact far beyond the original project settings

Programmatic Uptake Milestones

  • scale-up plans

    7 of 7 Countries

    established scale-up plans confirmed by National Tuberculosis Programs

  • placed orders

    7 of 7 Countries

    placed orders to procure pretomanid

  • programmatic use

    7 of 7 Countries

    implementing BPaL in programmatic use, partially or nationally

  • Patients Treated

    7 of 7 Countries

    updated national TB treatment guidelines

Operational Research Milestones

  • Regulatory Submissions

    7 of 7 Countries

    completed regulatory submissions

  • Philippines, Ukraine, and Uzbekistan

    achieved regulatory approval of pretomanid

  • Operational Research Programs

    90.8%

    success rate for people with DR-TB treated in LIFT-TB program

  • Patients Treated

    7 of 7 Countries

    have completed enrollment of operational research studies

Capacity Building Milestones

  • 1,244 Health Professionals

    trained in LIFT-TB countries

  • 7 of 7 Countries

    performed clinical training

  • 6 of 6 Countries

    performed data management training

  • 7 of 7 Countries

    developed training materials

Country Dashboards

LIFT-TB partners are ensuring that patients with highly drug-resistant TB have access to short, simplified therapy. In doing so, they are also building capacity to respond to the disease at a health system level. These dashboards provide an overview of where each country stands.

Updated August 2024

  • Indonesia

    Indonesia

    Global rank in DR-TB burden: 4

    Patients enrolled: 87

    Target enrollment: 100

    Health professionals trained: 1622

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 152%

  • Kyrgyzstan

    Kyrgyzstan

    Global rank in DR-TB burden: 25

    Patients enrolled: 50

    Target enrollment: 50

    Health professionals trained: 191

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 49% 

  • Myanmar

    Myanmar

    Global rank in DR-TB burden: 11

    Patients enrolled: 100

    Target enrollment: 100

    Health professionals trained: 121

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 92%

  • Philippines

    Philippines

    Global rank in DR-TB burden: 6

    Patients enrolled: 99

    Target enrollment: 99

    Health professionals trained: 520

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 96%

  • Ukraine

    Ukraine

    Global rank in DR-TB burden: 8

    Patients enrolled: 153

    Target enrollment: 135

    Health professionals trained: data not available

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 80%

  • Uzbekistan

    Uzbekistan

    Global rank in DR-TB burden: 14

    Patients enrolled: 43

    Target enrollment: 50

    Health professionals trained: 110

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025):‍ ‍39%

  • Vietnam

    Viet Nam

    Global rank in DR-TB burden: 9

    Patients enrolled: 40

    Target enrollment: 100

    Health professionals trained: 729

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

    Share of DR-TB burden that could be covered by procured pretomanid (cumulative, 2023–2025): 63%